Several factors—such as bone pain and year of metastasis—are predictive of skeletal-related events (SREs) among patients being treated for bone metastatic castration-resistant prostate cancer (mCRPC), according to a study published in Cancer.1
Researchers evaluated data from 233 patients with non-metastatic CRPC who developed bone metastases during follow-up to determine factors predictive of SREs. Patients were a median age of 75 years at time of diagnosis.
At a median follow-up of 7.8 months, the researchers noted 88 patients who had an SRE.
A more recent year of metastasis, prostate-specific antigen doubling time of at least 9 months as opposed to less than 9 months, as well as bone pain were associated with SRE risk upon univariable analysis.
Year of metastasis, a biopsy Gleason score of at least 7, radiotherapy as the primary localized treatment, and bone pain were associated with SRE risk upon multivariable analysis.
RELATED: GATA2 in Prostate Cancer: A Promising Biomarker
“If confirmed, future trials should focus on prolonging life and reducing SRE risk in patients with mCRPC with bone pain,” the authors concluded.
- Klaassen Z, Howard LE, de Hoedt A, et al. Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer. Cancer. 2016 27 Dec. doi: 10.1002/cncr.30505 [Epub ahead of print]